Base de dados : MEDLINE Pesquisa : Transtornos and Linfoproliferativos [Palavras] Referências encontradas : 6631 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 664

ir para página

1 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 23498038 [Au] Autor: Mendelson M; Barday Z; Eastman R; Le Feuvre D; Candy S; Wu HT; Swanepoel C [Ad] Endereço: Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa. marc.mendelson@uct.ac.za [Ti] Título: Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus. [So] Source: S Afr Med J;102(12):924-6, 2012 Dec. [Is] ISSN: 0256-9574 [Cp] País de publicação: South Africa [La] Idioma: eng [Ab] Resumo: Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant after renal transplantation. Withdrawal of sirolimus from the immunosuppression regimen may reduce B-cell surveillance. We present a case of rapidly progressive central nervous system (CNS) polymorphic Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder following the withdrawal of sirolimus. [Mh] Termos MeSH primário: Rejeição de Enxerto/quimioterapia Transplante de Rim Transtornos Linfoproliferativos/etiologia Complicações Pós-Operatórias Sirolimo/uso terapêutico [Mh] Termos MeSH secundário: Adulto Biópsia Progressão da Doença Humanos Imunossupressão Imunossupressores/uso terapêutico Transtornos Linfoproliferativos/diagnóstico Masculino Tomografia Computadorizada por Raios X [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Immunosuppressive Agents); 53123-88-9 (Sirolimus) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 130318 [St] Status: MEDLINE [do] DOI: 10.7196/samj.5500

2 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 23169501 [Au] Autor: Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T [Ad] Endereço: University Children's Hospital, Tübingen, Germany. [Ti] Título: Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. [So] Source: J Clin Oncol;31(1):39-48, 2013 Jan 1. [Is] ISSN: 1527-7755 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: PURPOSE: Reactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. PATIENTS AND METHODS: To improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) -specific T cells by using an interferon gamma (IFN-γ) capture technique. RESULTS: We report on the use of adoptive transfer of EBNA-1-specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1-specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. CONCLUSION: Adoptive ex vivo transfer of EBNA-1-specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT. [Mh] Termos MeSH primário: Transferência Adotiva Antígenos Nucleares do Vírus Epstein-Barr/metabolismo Herpesvirus Humano 4/fisiologia Transtornos Linfoproliferativos/terapia Neoplasias/complicações Transplante de Células-Tronco/efeitos adversos Linfócitos T/imunologia [Mh] Termos MeSH secundário: Adolescente Adulto Criança Pré-Escolar Terapia Combinada Infecções por Vírus Epstein-Barr/imunologia Infecções por Vírus Epstein-Barr/metabolismo Infecções por Vírus Epstein-Barr/virologia Feminino Seguimentos Doença Enxerto-Hospedeiro/imunologia Doença Enxerto-Hospedeiro/mortalidade Doença Enxerto-Hospedeiro/prevenção & controle Humanos Interferon gama/metabolismo Transtornos Linfoproliferativos/etiologia Transtornos Linfoproliferativos/metabolismo Masculino Meia-Idade Estadiamento de Neoplasias Neoplasias/terapia Prognóstico Linfócitos T/metabolismo Linfócitos T/transplante Transplante Homólogo Carga Viral/imunologia Adulto Jovem [Pt] Tipo de publicação: COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (EBV-encoded nuclear antigen 1); 0 (Epstein-Barr Virus Nuclear Antigens); 82115-62-6 (Interferon-gamma) [Em] Mês de entrada: 1302 [Cu] Atualização por classe: 130514 [Lr] Data última revisão: 130514 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 121231 [St] Status: MEDLINE [do] DOI: 10.1200/JCO.2011.39.8495

3 / 6631

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 23037764 [Au] Autor: Kimura H [Ti] Título: [Epstein-Barr virus and hematological neoplasms]. [So] Source: Rinsho Ketsueki;53(10):1874-82, 2012 Oct. [Is] ISSN: 0485-1439 [Cp] País de publicação: Japan [La] Idioma: jpn [Mh] Termos MeSH primário: Infecções por Vírus Epstein-Barr/patologia Neoplasias Hematológicas/patologia Transtornos Linfoproliferativos/patologia [Mh] Termos MeSH secundário: Infecções por Vírus Epstein-Barr/complicações Perfilação da Expressão Gênica Neoplasias Hematológicas/diagnóstico Neoplasias Hematológicas/terapia Neoplasias Hematológicas/virologia Humanos Transtornos Linfoproliferativos/terapia Transtornos Linfoproliferativos/virologia [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 121005 [St] Status: MEDLINE

4 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22711849 [Au] Autor: Wang TF; Klein JL; Woodard PK; Hassan A; Joseph SM; Ewald GA; Uy GL [Ad] Endereço: Washington University School of Medicine, St Louis, MO, USA. [Ti] Título: Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. [So] Source: J Clin Oncol;30(27):e278-82, 2012 Sep 20. [Is] ISSN: 1527-7755 [Cp] País de publicação: United States [La] Idioma: eng [Mh] Termos MeSH primário: Neoplasias Cardíacas/patologia Transplante de Coração Imunossupressão/efeitos adversos Transtornos Linfoproliferativos/patologia [Mh] Termos MeSH secundário: Adulto Antineoplásicos/uso terapêutico Ácidos Borônicos/uso terapêutico Feminino Neoplasias Cardíacas/induzido quimicamente Neoplasias Cardíacas/quimioterapia Humanos Imunossupressores/administração & dosagem Transtornos Linfoproliferativos/induzido quimicamente Transtornos Linfoproliferativos/quimioterapia Plasmocitoma Pirazinas/uso terapêutico [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antineoplastic Agents); 0 (Boronic Acids); 0 (Immunosuppressive Agents); 0 (Pyrazines); 0 (bortezomib) [Em] Mês de entrada: 1212 [Cu] Atualização por classe: 130513 [Lr] Data última revisão: 130513 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120918 [St] Status: MEDLINE [do] DOI: 10.1200/JCO.2011.39.5855

5 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 23321251 [Au] Autor: Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP [Ad] Endereço: Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA 02215, USA. [Ti] Título: MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. [So] Source: Blood;121(11):2051-8, 2013 Mar 14. [Is] ISSN: 1528-0020 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström macroglobulinemia (WM) patients. MYD88 L265P was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P < 1.5 × 10(-5) for WM vs other cohorts). Real-time AS-PCR identified IgM MGUS patients progressing to WM and showed a high rate of concordance between MYD88 L265P ΔCT and BM disease involvement (r = 0.89, P = .008) in WM patients undergoing treatment. These studies identify MYD88 L265P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR assays with potential use in diagnostic discrimination and/or response assessment. The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis. [Mh] Termos MeSH primário: Linfócitos B Imunoglobulina M Transtornos Linfoproliferativos/genética Gamopatia Monoclonal de Significância Indeterminada/genética Fator 88 de Diferenciação Mieloide/genética Reação em Cadeia da Polimerase/métodos Macroglobulinemia de Waldenström/genética [Mh] Termos MeSH secundário: Adulto Idoso Alelos Substituição de Aminoácidos/fisiologia Linfócitos B/metabolismo Linfócitos B/patologia Sequência de Bases Estudos de Casos e Controles Transformação Celular Neoplásica/genética Análise Mutacional de DNA Humanos Imunoglobulina M/genética Imunoglobulina M/metabolismo Leucina/genética Transtornos Linfoproliferativos/imunologia Masculino Meia-Idade Dados de Sequência Molecular Gamopatia Monoclonal de Significância Indeterminada/imunologia Gamopatia Monoclonal de Significância Indeterminada/metabolismo Polimorfismo de Nucleotídeo Único/fisiologia Prolina/genética [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Immunoglobulin M); 0 (MYD88 protein, human); 0 (Myeloid Differentiation Factor 88); 147-85-3 (Proline); 61-90-5 (Leucine) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: AIM; IM [Da] Data de entrada para processamento: 130315 [St] Status: MEDLINE [do] DOI: 10.1182/blood-2012-09-454355

6 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 23364482 [Au] Autor: Jaksch P; Wiedemann D; Kocher A; Muraközy G; Augustin V; Klepetko W [Ad] Endereço: Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria. [Ti] Título: Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients. [So] Source: Transplantation;95(5):766-72, 2013 Mar 15. [Is] ISSN: 1534-6080 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: BACKGROUND: Posttransplantation lymphoproliferative disorder (PTLD), a complication of lung transplantation with an incidence ranging from as much as 20%, is mainly associated with Epstein-Barr virus (EBV) infection. In renal transplantation, the use of immunoglobulin (Ig) cytomegalovirus (CMV) prophylaxis, which contains anti-EBV antibodies, resulted in a significant lower incidence of PTLD. In this study, we report our experience with PTLD in lung transplantation with CMV Ig prophylaxis. METHODS: One-thousand one-hundred fifty-seven consecutive patients who underwent lung transplantation at the Medical University of Vienna between November 1989 and December 2011 were included in this retrospective analysis on PTLD. CMV prophylaxis consisted in all patients of antiviral drugs (ganciclovir/valganciclovir) combined with anti-CMV Ig for 4 weeks. RESULTS: A total of 18 patients (1.5%) developed PTLD of B cell origin. Fifteen patients were diagnosed in the first posttransplantation year, and three patients, beyond 1 year. One- and three-year survival after diagnosis of PTLD was 50% and 38%, respectively. CONCLUSION: The incidence of PTLD in our center is extremely low when compared with the scientific literature. We hypothesize that CMV Ig prophylaxis also protects from EBV-associated PTLD. [Mh] Termos MeSH primário: Imunoglobulinas/uso terapêutico Transplante de Pulmão/efeitos adversos Transtornos Linfoproliferativos/prevenção & controle [Mh] Termos MeSH secundário: Adulto Idoso Anticorpos Antivirais/sangue Feminino Herpesvirus Humano 4/imunologia Herpesvirus Humano 4/isolamento & purificação Humanos Incidência Transplante de Pulmão/mortalidade Transtornos Linfoproliferativos/epidemiologia Masculino Meia-Idade Estudos Retrospectivos Fatores de Risco [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antibodies, Viral); 0 (Immunoglobulins); 0 (cytomegalovirus-specific hyperimmune globulin) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 130319 [St] Status: MEDLINE [do] DOI: 10.1097/TP.0b013e31827df7a7

7 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22497716 [Au] Autor: Kawabe S; Ito Y; Gotoh K; Kojima S; Matsumoto K; Kinoshita T; Iwata S; Nishiyama Y; Kimura H [Ad] Endereço: Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan. [Ti] Título: Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. [So] Source: Cancer Sci;103(8):1481-8, 2012 Aug. [Is] ISSN: 1349-7006 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Epstein-Barr virus (EBV) infects various types of lymphocytes and is associated with not only B cell-origin lymphoma, but also T or natural killer cell lymphoproliferative diseases (T/NK LPD). Recently, we established a novel assay to identify EBV-infected cells using FISH. Using this assay, dual staining with antibodies to both surface antigens and an EBV-encoded small RNA (EBER) probe can be performed. In the present study, we applied this recently developed FISH assay to EBV-associated T/NK LPD to confirm its diagnostic utility. Using FISH, we prospectively analyzed peripheral blood from patients with suspected EBV-associated T/NK LPD. The results were compared with those obtained using immunobead sorting followed by quantitative PCR. In all, 26 patients were included study. Using FISH, 0.15-67.0% of peripheral blood lymphocytes were found to be positive for EBER. Dual staining was used to determine EBER-positive cell phenotypes in 23 of 26 subjects (88.5%). In five of seven patients with hydroa vacciniforme-like lymphoma (an EBV-positive cutaneous T cell lymphoma), EBER-positive cells were identified as CD3(+) CD4(-) CD8(-) TCRγδ(+) T cells. Furthermore, in a 25-year-old male patient with systemic EBV-positive T cell LPD, two lymphocyte lineages were positive for EBER: CD4(+) CD8(-) and CD4(-) CD8(+) T cells. Thus, we confirmed that our newly developed assay is useful for quantifying and characterizing EBV-infected lymphocytes in EBV-associated T/NK LPD and that it can be used not only to complement the pathological diagnosis, but also to clarify the pathogenesis and to expand the spectrum of EBV-associated diseases. [Mh] Termos MeSH primário: Infecções por Vírus Epstein-Barr/imunologia Citometria de Fluxo/métodos Herpesvirus Humano 4/imunologia Hibridização In Situ Fluorescente/métodos Células Matadoras Naturais Transtornos Linfoproliferativos/diagnóstico [Mh] Termos MeSH secundário: Adolescente Adulto Criança Pré-Escolar Infecções por Vírus Epstein-Barr/complicações Feminino Genes Codificadores dos Receptores de Linfócitos T Herpesvirus Humano 4/genética Humanos Lactente Células Matadoras Naturais/imunologia Transtornos Linfoproliferativos/patologia Transtornos Linfoproliferativos/virologia Masculino Meia-Idade Estudos Prospectivos Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120727 [St] Status: MEDLINE [do] DOI: 10.1111/j.1349-7006.2012.02305.x

8 / 6631

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo

[PMID]: 21906576 [Au] Autor: Abou-Nassar KE; Kim HT; Blossom J; Ho VT; Soiffer RJ; Cutler CS; Alyea EP; Koreth J; Antin JH; Armand P [Ad] Endereço: Department of Medicine, Division of Hematology, University of Ottawa, Ontario, Canada. [Ti] Título: The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. [So] Source: Biol Blood Marrow Transplant;18(5):708-15, 2012 May. [Is] ISSN: 1523-6536 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) need access to specialized care. We hypothesized that access to the transplant center after HSCT may be challenging for patients living in geographically distant areas, and that this would have an adverse effect on their outcome. We analyzed 1912 adult patients who underwent allogeneic HSCT at the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) between 1996 and 2009 and who resided within 6 hours driving time of the institution. Driving time from primary residence to DF/BWCC based on zipcode was determined using geographic information systems. The median driving time (range) to DF/BWCC was 72 (2-358) minutes. When patients were stratified by driving time quartile, overall survival (OS) after HSCT was similar in the first year but worse after 1 year in patients in the top quartile (≥ 160 minutes driving time). In a landmark analysis of the 909 patients alive and free of disease at 1 year, 5-year OS was 76% and 65% for patients in the first (≤ 40 minutes) and fourth (≥ 160 minutes) quartiles, respectively (P = .027). This was confirmed in a multivariable analysis. The difference appeared to be mostly because of an increase in nonrelapse mortality. The number of visits to the transplant center between day 100 and 365 after HSCT declined significantly with increasing driving time to the transplant center, which was independently associated with worse survival. Long driving time to the transplant center is associated with worse OS in patients alive and disease-free 1 year after HSCT, independently of other patient-, disease-, and HSCT-related variables. This may be in part related to the lower frequency of post-HSCT visits in patients living farther away. [Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas Transtornos Linfoproliferativos/terapia Topografia Médica [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Canadá Feminino Humanos Transtornos Linfoproliferativos/mortalidade Masculino Meia-Idade Análise Multivariada Estudos Retrospectivos Análise de Sobrevida Fatores de Tempo Transplante Homólogo Resultado de Tratamento Estados Unidos [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Mês de entrada: 1305 [Cu] Atualização por classe: 130503 [Lr] Data última revisão: 130503 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120423 [St] Status: MEDLINE [do] DOI: 10.1016/j.bbmt.2011.08.022

9 / 6631

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22293123 [Au] Autor: Petersdorf EW [Ad] Endereço: Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. epetersd@fhcrc.org [Ti] Título: Of genes, blocks, and haplotypes. [So] Source: Biol Blood Marrow Transplant;18(4):494-6, 2012 Apr. [Is] ISSN: 1523-6536 [Cp] País de publicação: United States [La] Idioma: eng [Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/prevenção & controle Cadeias beta de HLA-DP/imunologia Transplante de Células-Tronco Hematopoéticas Transtornos Linfoproliferativos/imunologia Fator de Necrose Tumoral alfa/imunologia [Mh] Termos MeSH secundário: Feminino Humanos Masculino [Pt] Tipo de publicação: COMMENT; JOURNAL ARTICLE [Nm] Nome de substância: 0 (HLA-DP beta-Chains); 0 (HLA-DPB1 antigen); 0 (Tumor Necrosis Factor-alpha) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120314 [St] Status: MEDLINE [do] DOI: 10.1016/j.bbmt.2012.01.016

10 / 6631

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo

[PMID]: 22245598 [Au] Autor: Ponce DM; Lubin M; Gonzales AM; Byam C; Wells D; Ferrante R; Heller G; Giralt S; Papadopoulos EB; Kernan NA; Scaradavou A; Barker JN [Ad] Endereço: Adult Bone Marrow Transplantation, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. [Ti] Título: The use of back-up units to enhance the safety of unrelated donor cord blood transplantation. [So] Source: Biol Blood Marrow Transplant;18(4):648-51, 2012 Apr. [Is] ISSN: 1523-6536 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The inability to obtain additional stem cells is a disadvantage of unrelated donor cord blood transplantation (CBT). Moreover, in the event of problems with unit shipment, compromised unit quality, thaw mishaps, or graft failure, the time to secure a back-up graft could be unacceptable. Emergent shipment of 1 to 2 back-up units that have been previously typed and reserved could overcome this limitation. However, the advantages of this approach are not established. Therefore, we present our use of back-up units over a 5.5-year period. Six of 121 CBT recipients (5%) required back-up unit infusion. Indications included shipment mishaps (n = 2), poor unit viability (n = 2), significant infusion reaction (n = 1), and graft failure (n = 1). Lack of back-up units would have caused transplantation delay or infusion of inferior-quality units. Five of the 6 patients achieved sustained donor engraftment. We demonstrate that back-up units are emergently required in a significant minority of patients, supporting the incorporation of at least 1 back-up unit in cord blood (CB) selection algorithms to enhance CBT safety. [Mh] Termos MeSH primário: Transplante de Células-Tronco de Sangue do Cordão Umbilical Rejeição de Enxerto/terapia Doença Enxerto-Hospedeiro/prevenção & controle Transtornos Linfoproliferativos/terapia Condicionamento Pré-Transplante Transplantes/provisão & distribuição [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Criança Pré-Escolar Feminino Rejeição de Enxerto/imunologia Doença Enxerto-Hospedeiro/imunologia Teste de Histocompatibilidade Humanos Lactente Transtornos Linfoproliferativos/imunologia Masculino Meia-Idade Estudos Retrospectivos Manejo de Espécimes Transplante Homólogo Doadores não Relacionados [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S. [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120314 [St] Status: MEDLINE [do] DOI: 10.1016/j.bbmt.2011.12.588

---

página 1 de 664

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliação
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliação
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliação

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde